METTL3 is usually considered to represent a diagnosed malignant phenotype with a poor prognosis, but the finding that METTL3 can act as a prognostic factor in RCC suggests that METTL3 has complexity in serving as a cancer biomarker. This evidence concerns the gene METTL3 and renal cell carcinoma.